Search

everythinglearnresearchcommunity

for

Search:↓

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

A user shared 4-month progress pictures using a daily Hims fin/min/ketoconazole/biotin hybrid spray for hair loss, reporting positive results. Suggestions included adding microneedling to the routine.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

A user reported full recovery from Post Finasteride Syndrome after 6 months of HCG treatment. They used 250IU of HCG three times a week.

The conversation is about the side effects of finasteride, including Post Finasteride Syndrome, with varied personal experiences and differing views on the credibility of information sources. Some participants also discuss using minoxidil as a hair loss treatment.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Pedro Pascal's full head of hair is likely due to genetics, finasteride, and possibly hair transplants. Many actors use finasteride to maintain their hair.

The user underwent a hair transplant 11 months ago and is satisfied with the results, regaining confidence. Post-operation treatments included oral minoxidil, finasteride, dutasteride, vitamin supplements, and occasional QR678 injections.

A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Hims reactivated a subscription without consent, leading to unauthorized charges for Finasteride and Minoxidil products, and refused to issue a refund until a bank dispute was filed. Users discussed alternative, cheaper sources for these treatments and shared similar negative experiences with Hims.

A user shared his experience of having two healthy children while continuously using finasteride (Fin) for hair loss, challenging fears about its potential impact on fetal development. The discussion that followed included various perspectives, with some users sharing similar experiences, others expressing concerns about potential risks, and some emphasizing the need for more substantial evidence before drawing conclusions.

A person shared their hair transplant experience, mentioning complications like excessive bleeding and density anxiety, and is using finasteride and minoxidil chewables. They traveled to Turkey for the procedure, paid around $3800, and are considering Mexico for future treatments; nicotine use is a concern for their recovery.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

Finasteride can affect hormone levels, potentially causing symptoms like puffy nipples and testicular pain, and may result in elevated prolactin and high testosterone. The user is seeking interpretation of these changes after taking finasteride.

The conversation is about a user's one-year progress after a 3,200 graft FUE hair transplant and their use of oral finasteride and minoxidil. People are impressed with the results and are discussing the effectiveness and cost of the treatment.

A user shared progress pictures after 40 days of using topical finasteride, minoxidil, and KX-826 following a hair transplant. They previously used Polaris NR-11, which contains finasteride and minoxidil, and experienced significant hair regrowth.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.

A user shared their 4-month progress using a serum with Minoxidil 10%, Progesterone, Azelaic acid, Retinoic acid, Latanoprost, and Hydrocortisone, along with PRP and Fotona laser treatments. They are pleased with the results and plan to continue with more PRP and laser sessions, without using Finasteride.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

A 19-year-old trans man has been using Finasteride 1mg for a little over two months and is concerned about worsening hair loss, noting a fuzzy and soft hairline and crown. The user is upset as the hair loss appears worse than before starting the treatment.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

A user's 15 month progress with finasteride and minoxidil treatments, which have produced great results. Microneedling depth and frequency were discussed in the replies.